Brought to you by 
Houghten will buy combinatorial biology company ChromaXome
13 Jul 1999
Executive Summary
Houghten Pharmaceuticals (combinatorial chemistry) agreed to acquire private biotech ChromaXome, which calls its specialty combinatorial biology. HP will pay with a guaranteed 216,000 shares of common stock ($8.50 per share pre-announcement).
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Earnout
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Houghten will buy combinatorial biology company ChromaXome
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice